Disease · MONDO_0010888
Targets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 20
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | 5 | Gonadotropin-releasing hormone receptor agonist | Phase 3 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| PGR | Progesterone receptor | 5 | Progesterone receptor agonist; Progesterone receptor antagonist; Progesterone receptor modulator | Phase 2/3 | https://conductscience.org/library/genes/5241 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 2 | D2-like dopamine receptor agonist; Dopamine D2 receptor agonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 1 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 1 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| FGFR2 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2263 | Drugs and targets |
| FGFR3 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2261 | Drugs and targets |
| FGFR4 | Fibroblast growth factor receptor | 1 | Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2264 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Early phase 1 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| OXTR | Oxytocin receptor | 1 | Oxytocin receptor antagonist | Phase 2 | https://conductscience.org/library/genes/5021 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 1 | Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 1 | Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| SERPINC1 | Antithrombin-III | 1 | Antithrombin-III activator | Unknown | https://conductscience.org/library/genes/462 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010888/targets